Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics Inc (NQ: APLT )

4.890 +0.060 (+1.24%)
Streaming Delayed Price Updated: 1:24 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Applied Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates... 
Via Benzinga
Exposures Product Safety
Applied Therapeutics: Q4 Earnings Insights
Via Benzinga
(APLT) - Analyzing Applied Therapeutics's Short Interest
Via Benzinga
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder
Applied Therapeutics surges as FDA grants Priority Review to govorestat (AT-007) for Galactosemia treatment. If approved, it would be the first medication for Galactosemia. APLT also submits MAA to... 
Via Benzinga
Exposures Product Safety
Why Is Coupang (CPNG) Stock Up 4% Today?
Coupang stock is rallying on Wednesday as investors in CPNG celebrate the company beating out EPS and revenue estimates for Q4. 
Via InvestorPlace
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
Applied Therapeutics stock is rising higher on Wednesday alongside heavy trading of APLT following an update from the FDA. 
Via InvestorPlace
Applied Therapeutics Announces $100 Million Private Placement
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Rare Disease-Focused Applied Therapeutics Stock Trading Higher Today?
Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD Deficiency... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
From Applied Therapeutics
Via GlobeNewswire
Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.13% to 37,490.36 while the NASDAQ rose 0.25% to 14,546.77. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Turns Lower; ISM Services PMI Falls In December
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 70 points on Friday. The Dow traded down 0.19% to 37,369.52 while the NASDAQ rose 0.16% to 14,533.16. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Applied Therapeutics' Diabetes-Associated Heart Disease Drug Fails In Phase 3 Study, Stock Plunges
Applied Therapeutics Inc (NASDAQ: APLT) released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.